AAIC 2025 Abstract
Potential Eligibility for Lecanemab in a Cohort of Alzheimer’s Dementia Patients from India
Study in peoplePopulations
Abstract
Background: Lecanemab, a monoclonal antibody targeting amyloid, has been approved as disease‐modifying treatment for Alzheimer’s disease (AD) and is gradually gaining regulatory approvals across the globe.
